How Have the Numbers Shaped Up for Medicenna Therapeutics (NASDAQ:MDNA)

Earnings results for Medicenna Therapeutics (NASDAQ:MDNA)

Medicenna Therapeutics Corp. is expected* to report earnings on 05/28/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $-0.05.

Analyst Opinion on Medicenna Therapeutics (NASDAQ:MDNA)

4 Wall Street analysts have issued ratings and price targets for Medicenna Therapeutics in the last 12 months. Their average twelve-month price target is $10.00, predicting that the stock has a possible upside of 161.78%. The high price target for MDNA is $12.00 and the low price target for MDNA is $8.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Medicenna Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $10.00, Medicenna Therapeutics has a forecasted upside of 161.8% from its current price of $3.82. Medicenna Therapeutics has received no research coverage in the past 90 days.

Dividend Strength: Medicenna Therapeutics (NASDAQ:MDNA)

Medicenna Therapeutics does not currently pay a dividend. Medicenna Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Medicenna Therapeutics (NASDAQ:MDNA)

In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock. Only 10.33% of the stock of Medicenna Therapeutics is held by institutions.

Earnings and Valuation of Medicenna Therapeutics (NASDAQ:MDNA

Earnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.34) per share. The P/E ratio of Medicenna Therapeutics is -16.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Medicenna Therapeutics is -16.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Medicenna Therapeutics has a P/B Ratio of 4.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here